Kymera Therapeutics (KYMR) Tops Q4 EPS by 3c

Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.60), $0.03 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $22.09 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates